The in vivo efficacy of THLs was investigated in a model of type VII mucopolysaccharidosis (MPS), which is caused by mutations in the gene encoding the lysosomal enzyme β-glucuronidase (GUSB) [36]. Here, GUSB is linked to mucopolysaccharidosis type 7.